Core Insights - The company has shown significant growth in innovative product revenue, reaching RMB 7.8 billion in the first half of 2025, a year-on-year increase of 27.2%, indicating the effectiveness of its transformation towards innovative drugs [1][3] - The company continues to invest heavily in research and development, with R&D costs amounting to approximately RMB 3.188 billion, representing 18.1% of total revenue [1][4] Innovative Product Approval - In the first half of 2025, the company received approval for two innovative products from the National Medical Products Administration, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIaN01 Injection), which significantly supported the growth of innovative product revenue [3] - The company also maintained a robust performance in its generic drug business, with five generic drugs approved during the reporting period, indicating competitiveness in traditional pharmaceutical operations [3] Financial Performance - The total revenue for 2024 reached RMB 28.919 billion, a 3.35% increase from RMB 27.982 billion in 2023, while the profit attributable to shareholders surged by 50.09% to RMB 3.5 billion compared to RMB 2.332 billion in 2023, reflecting a notable improvement in profitability [3] - The company's financial condition remains stable, with a current ratio of 1.26 and a quick ratio of 1.14, indicating enhanced short-term solvency compared to 2023 [5] R&D Investment and Strategy - The company’s commitment to R&D is evident, with approximately 95.7% of total R&D expenditures accounted for in the profit and loss statement, underscoring its strategic focus on sustainable development [4] - The company has established a clear development direction in four core therapeutic areas: oncology, liver disease and metabolism, respiratory system, and surgical analgesia, which aids in building competitive advantages and improving R&D efficiency [4] Cash Flow and Financial Structure - Despite a generally stable financial status, the company’s cash flow situation requires attention, with a net cash flow per share of -RMB 0.07, reflecting ongoing R&D and acquisition investments [6] - The asset-liability ratio improved to 34.60% in 2024 from 39.99% in 2023, indicating a more conservative financial leverage approach [6]

Group 1 - The core point of the article highlights that China Biopharmaceutical reported a significant increase in its financial performance for the first half of 2025, with a notable rise in both revenue and profit [3] - The company's revenue for the six months ending June 30, 2025, was approximately RMB 17.575 billion, reflecting a year-on-year growth of 10.7% [3] - The profit attributable to the parent company holders from continuing operations was around RMB 3.389 billion, showing a substantial year-on-year increase of 140.2% [3] - Basic earnings per share were approximately RMB 0.1882, which represents a year-on-year growth of 145.7% [3] - The profit growth was primarily driven by significant revenue increases, as well as gains from dividend income and changes in the fair value of investments [3] Group 2 - After adjustments, the basic profit attributable to the parent company holders was approximately RMB 3.088 billion, marking a substantial year-on-year increase of 101.1% [1] - The board of directors announced an interim dividend of HKD 0.05 per share [1]

本文源自：财华网 于报告期內，集团共有2个创新产品获NMPA批准上市，分別为普坦宁(美洛昔康注射液(II))和安啟新(注 射用重组人凝血因子VIIaN01)。2025年上半年，集团创新产品收入达到78亿元，同比增长27.2%。除创 新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。 【财华社讯】中国生物制药(01177.HK)公布，截至2025年6月30日止六个月，收入约175.75亿元(人民币, 下同)，同比增加10.7%；归母净利润33.89亿元，同比增加12.3%；基本每股盈利18.82分。拟派中期股息 每股5港仙。 ...

Core Viewpoint - China Biologic Products (1177.HK) reported a mid-year profit attributable to shareholders of 3.389 billion yuan, representing a year-on-year increase of 12.31% [1] Financial Performance - Revenue from continuing operations reached 17.575 billion yuan, up 10.71% year-on-year [1] - Gross margin stood at 82.5%, an increase of 0.4 percentage points [1] - Earnings per share were 0.1882 yuan, with an interim dividend of 0.05 HKD declared [1] Product Development - The company received NMPA approval for two innovative products, Putan Ning and Anqi Xin, during the reporting period [1] - Revenue from innovative products amounted to 7.8 billion yuan, reflecting a year-on-year growth of 27.2% [1] - Additionally, five generic drugs were approved by NMPA, with overall revenue from generics maintaining positive growth in the first half of the year [1]

8月18日下午，中国生物制药在港交所公告，2025年上半年集团录得收入约人民币175.7亿元，较去年同 期增长约10.7%；来自持续经营业务之归属于母公司持有者盈利约人民币33.9亿元，较去年增加约 140.2%。 ...

中国生物制药(01177)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入人民币175.7亿元(单 位下同)，同比增加10.7%;母公司持有人应占溢利33.89亿元，同比增加12.31%;财务报表所示来自持续经 营业务的归属于母公司持有者盈利33.9亿元，同比增加140.2%;基本每股盈利18.82分，拟派发中期股息 每股5港仙。 一直以来，本集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的 资金投入。截至2025年6月30日止6个月，研究与开发成本约31.88亿元，占本集团收入约18.1%，连同已 资本化的研发总开支出在内，约95.7%已计入损益表中。 于报告期内，本集团共有2个创新产品获NMPA批准上市，分别为普坦宁(美洛昔康注射液(II))和安启新 (注射用重组人凝血因子VIIa N01)。 2025年上半年，本集团创新产品收入达到78亿元，同比增长 27.2%。除创新产品外，本集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持 正增长。 ...

每经AI快讯，8月18日，中国生物制药在港交所公告，上半年实现营收175.7亿元，同比增长10.7%；实 现净利润33.9亿元，同比增长140.2%。 （文章来源：每日经济新闻） ...

一直以来，本集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的 资金投入。截至2025年6月30日止6个月，研究与开发成本约31.88亿元，占本集团收入约18.1%，连同已 资本化的研发总开支出在内，约95.7%已计入损益表中。 中国生物制药(01177)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入人民币175.7亿元(单 位下同)，同比增加10.7%;母公司持有人应占溢利33.89亿元，同比增加12.31%;财务报表所示来自持续经 营业务的归属于母公司持有者盈利33.9亿元，同比增加140.2%;基本每股盈利18.82分，拟派发中期股息 每股5港仙。 于报告期内，本集团共有2个创新产品获NMPA批准上市，分别为普坦宁(美洛昔康注射液(II))和安启新 (注射用重组人凝血因子VIIa N01)。2025年上半年，本集团创新产品收入达到78亿元，同比增长 27.2%。除创新产品外，本集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持 正增长。 ...

格隆汇8月18日丨中国生物制药(01177.HK)发布公告，截至2025年6月30日止六个月，于本期间内，集团 录得收入约人民币175.75亿元，较去年同期增长约10.7%。财务报表所示的来自持续经营业务的归属于 母公司持有者盈利约人民币33.89亿元，较去年增加约140.2%。基于财务报表所示的来自持续经营业务 的归属于母公司持有者盈利计算的每股基本盈利约人民币18.82分，较去年增加约145.7%。财务报表所 示的来自持续经营业务的归属于母公司持有者盈利同比增长主要受惠于本期间收入明显增长及股息收益 和投资公允价值变动收益明显增长。扣除已终止经营业务的归属于母公司持有者应占盈利、应占联营公 司及合营公司盈利及亏损(扣除相关税项及非控制权益)、若干资产及负债的公允价值变动及一次性调整 的减值(扣除相关税项及非控制权益)，流动权益投资的公允价值亏损╱(利润)净额(扣除相关税项及非控 制权益)，股权激励费用(扣除相关税项及非控制权益)，可转换债券债务部份的利息费用及汇兑损失 ╱(收益)等的影响后，归属于母公司持有者的基本溢利(非香港财务报告准则指标)约人民币30.88亿元， 较去年同期大幅增长约101.1%。董 ...

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股票編號：1177） 截至二零二五年六月三十日止六個月之中期業績公告 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至六月三十日止六個月 | | | | | 二零二五年 | 二零二四年 | 變動 | | | 人民幣億元 | 人民幣億元 | % | | 收入 | 175.7 | 158.7 | +10.7% | | 毛利率(%) | 82.5% | 82.1% | +0.4百分點 | | （附註1） 銷售及管理費用佔收入比率(%) | 42.9% | 43.1% | -0.2百分點 | | 研發費用佔收入比率(%) | 18.1% | 16.2% | +1.9百分點 | | 來自持續經營業務之歸屬於母公司持有者盈利 | | | | | （附註2） 財務報表所示 | 33.9 | 14.1 | +140.2% | | （附註3） 基本溢利 | 30.9 | 15.4 | +101.1% | | （附註4） 創新產品收入 | 78.0 | 61.3 | +27.2% | | 佔收入 | ...